natgillin/translations-raw huggingface dataset:
6 mastceller/ baseofile, så vel som hæmning af dannelsen af adhæsionsmolekylet P- selektin på endothelieceller.
These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/ basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells.
I en enkeltdosis- undersøgelse med voksne påvirkede desloratadin 5 mg ikke standardmålene for evnen til at flyve, inklusive fremhævelse af subjektiv søvnighed, eller opgaver relaterede til flyvning.
In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.
I kliniske undersøgelser påvirkede desloratadin ved en daglig dosis på 7, 5 mg ikke den psykomotoriske præstation.
Desloratadine given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
Pseudoephedrinsulfat (d- isoephedrinsulfat) er et sympatomimetisk stof med hovedsageligt α- mimetisk aktivitet sammenlignet med β- aktivitet.
Pseudoephedrine sulphate (d-isoephedrine sulphate) is a sympathomimetic agent with mostly α -mimetic activity in comparison with the β -activity.
Pseudoephedrinsulfat giver en nasal dekongestant virkning efter peroral administration p. g. a. dets vasokonstriktive virkning.
Pseudoephedrine sulphate provides a nasal decongestant effect after oral administration due to its vasoconstrictive action.
Det har en indirekte sympatomimetisk virkning primært p. g. a. frigørelsen af adrenerge mediatorer fra de postganglionære nerveender.
It has an indirect sympathomimetic effect due primarily to the release of adrenergic mediators from the post-ganglionic nerve endings.
Peroral administration af pseudoephedrin ved den anbefalede dosis kan forårsage anden sympatomimetisk virkning, såsom øget blodtryk, takykardi eller manifestationer af spænding i centralnervesystemet.
Oral administration of pseudoephedrine at the recommended dose can cause other sympathomimetic effects, such as increased blood pressure, tachycardia or manifestations of central nervous system excitation.
Heraf fik 414 af disse Aerinaze - tabletter.
The clinical efficacy and safety of Aerinaze tablets was evaluated in two, 2-week multicentre, randomized parallel group clinical trials involving 1,248 patients 12 to 78 years of age with seasonal allergic rhinitis, 414 of whom received Aerinaze tablets.
I begge undersøgelser viste det sig, at antihistamin- effekten af Aerinaze- tabletter, målt som total symptom- score uden nasal tilstopning, var signifikant bedre end behandling med pseudoephedrin alene i en periode på 2 uger.
In both trials, the antihistaminic efficacy of Aerinaze tablets as measured by total symptom score, excluding nasal congestion, was significantly greater than pseudoephedrine alone over the 2-week treatment period.
Derudover var dekongestant- virkningen af Aerinaze- tabletter, målt som nasal tilstopning, signifikant bedre end behandling med desloratadin alene i en periode på 2 uger.
In addition, the decongestant efficacy of Aerinaze tablets, as measured by nasal stuffiness/ congestion, was significantly greater than desloratadine alone over the 2-week treatment period.
Der var ingen signifikante forskelle i virkningen af Aerinaze- tabletter i forskellige subgrupper af patienter defineret ved køn, alder eller race.
There were no significant differences in the efficacy of Aerinaze tablets across subgroups of patients defined by gender, age, or race.
Desloratadin og pseudoephedrin:
Desloratadine and Pseudoephedrine:
I en enkeltdosis- farmakokinetisk undersøgelse med Aerinaze blev plasmakoncentration af desloratadin målt inden for 30 minutter fra administration.
7 In a single dose pharmacokinetic study with Aerinaze, plasma concentration of desloratadine can be detected within 30 minutes of administration.
1, 09 ng/ ml og 31, 6 ng• time/ ml blev set.
The mean time to maximum plasma concentrations (Tmax) for desloratadine occurred at approximately 4-5 hours post dose and mean peak plasma concentrations (Cmax) and area under the concentration-time curve (AUC) of approximately 1.09 ng/ ml and 31.6 ng• hr/ ml, respectively, were observed.
263 ng/ ml og 4. 588 ng• time/ ml.
For pseudoephedrine, the mean Tmax occurred at 6-7 hours post dose and mean peak plasma concentrations (Cmax and AUC) of approximately 263 ng/ ml and 4,588 ng• hr/ ml, respectively, were observed.
Mad har ingen effekt på biotilgængeligheden (Cmax og AUC) for deloratadin eller pseudoephedrin.
Food had no effect on the bioavailability (Cmax and AUC) of desloratadine or pseudoephedrine.
Halveringstiden for desloratadin er 27, 4 timer.
The half-life for desloratadine is 27.4 hours.
Den tilsyneladende halveringstid for pseudoephedrin er 7, 9 timer.
The apparent half-life of pseudoephedrine is 7.9 hours.
Efter peroral administration af Aerinaze i 14 dage hos normale, raske frivillige, blev steady- state betingelser for desloratadin, 3- hydroxydesloratadin og pseudoephedrin nået på dag 10.
Following oral administration of Aerinaze for 14 days in normal healthy volunteers, steady-state conditions were reached on day 10 for desloratadine, 3-hydroxydesloratadine and pseudoephedrine.
1, 7 ng/ ml og 16 ng• time/ ml.
For desloratadine, mean steady state peak plasma concentrations (Cmax and AUC (0-12 h)) of approximately 1.7 ng/ ml and 16 ng• hr/ ml were observed, respectively.
For pseudoephedrin blev der set middel steady- state topplasmakoncentrationer (Cmax) og AUC (0- 12 timer)) på 459 ng/ ml og 4. 658 ng• time/ ml.
For pseudoephedrine, mean steady state peak plasma concentrations (Cmax and AUC (0-12 h)) of 459 ng/ ml and 4,658 ng• hr/ ml were observed.
6% af forsøgspersonerne nåede en højere desloratadinkoncentration i en række farmakokinetiske og kliniske undersøgelser.
In a series of pharmacokinetic and clinical trials, 6% of the subjects reached a higher concentration of desloratadine.
18% og 2%).
The prevalence of this poor metabolizer phenotype was greater among Blacks adults than Caucasians adults (18% vs.
Sikkerhedsprofilen hos disse forsøgspersoner adskilte sig imidlertid ikke fra den almene population.
2%) however the safety profile of these subjects was not different from that of the general population.
Disse personer havde ca.
In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine.
89 timer.
These subjects had a Cmax concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.
7 Desloratadin bindes moderat (83% - 87%) til plasmaproteiner.
Desloratadine is moderately bound (83% - 87%) to plasma proteins.
Pseudoephedrinsulfat:
Pseudoephedrine sulphate:
6.
Its elimination half-life in humans, at an approximate urinary pH of 6, ranges from 5 to 8 hours.
55- 75% af den administrerede dosis udskilles i uomdannet stand.
The active substance and its metabolite are excreted in urine; 55-75% of the administered dose is excreted unchanged.
I tilfælde af alkalisk urin sker en partiel resorption.
In case of alkalinization of the urine, a partial resorption takes place.
Et komponent- interaktionsstudie viste, at eksponeringen (Cmax og AUC) af pseudoephedrin, når det blev administreret alene, var bioævivalent med pseudoephedrin- eksponering efter administration af Aerinaze- tablet.
A component interaction study demonstrated that the exposure (Cmax and AUC) of pseudoephedrine following administration of pseudoephedrine alone was bioequivalent to pseudoephedrine exposure following administration of the Aerinaze tablet.
Derfor påvirker Aerinaze- formuleringen ikke absorptionen af pseudoephedrin.
Therefore absorption of pseudoephedrine was not affected by the Aerinaze formulation.
Pseudoephedrin formodes at krydse placenta og blod- hjernebarrieren.
Pseudoephedrine is presumed to cross the placenta and the haematoencephalic barrier.
Den aktive substans udskilles i modermælk hos kvinder.
The active substance is excreted in breast milk of lactating women.
Der er ikke udført prækliniske undersøgelser med Aerinaze.
No pre-clinical studies have been performed with Aerinaze.
Præ- kliniske data med desloratadin afslører imidlertid ingen særlig fare for mennesker vurderet ud fra konventionelle undersøgelser af sikkerhedsfarmakologi, toksicitet efter gentagne doser, genotoksicitet og reproduktionstoksicitet.
However, non-clinical data with desloratadine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction.
Manglen på karcinogent potentiale er vist i undersøgelser med desloratadin og loratadin.
The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.
Kombinationen af loratadin/ pseudoephedrinsulfat i akutte og multipeldosis- undersøgelser viste lav toksicitet.
8 The combination of loratadine/ pseudoephedrine sulphate used in acute and multiple-dose studies, exhibited a low order of toxicity.
Kombinationen var ikke mere toksisk end de enkelte komponenter, og de observerede virkninger var generelt relaterede til pseudoephedrindelen.
The combination was not more toxic than their individual components, and observed effects were generally related to the pseudoephedrine component.
Reproduktionstoksicitetsundersøgelser har vist, at kombinationen af loratadin/ pseudoephedrin ikke var teratogen, når kombinationen blev administreret peroralt til rotter i doser på op til 150 mg/ kg/ dag og til kaniner i doser på op til 120 mg/ kg/ dag.
During reproductive toxicity studies, the combination of loratadine/ pseudoephedrine was not teratogenic when administered orally to rats at doses up to 150 mg/ kg/ day and rabbits at doses up to 120 mg/ kg/ day.
Majsstivelse Mikrokrystallinsk cellulose Edetatdinatrium Citronsyre Stearinsyre Farvestof (indigo carmin E132 Aluminium lake).
Blue, immediate-release layer: maize starch microcrystalline cellulose edetate disodium citric acid stearic acid colorant (Indigo Carmine E132 Aluminum lake).
Hypromellose 2208 Mikrokrystallinsk cellulose Povidon K30 Silicadioxid Magnesiumstearat
White, sustained-release layer: hypromellose 2208 microcrystalline cellulose povidone K30 silicon dioxide magnesium stearate.
8 6. 3 Opbevaringstid
6.3 Shelf life
Opbevares i den ydre karton.
Keep the blisters in the outer carton.
Aerinaze leveres i blisterkort af laminatblisterfilm og folielåg.
Aerinaze is supplied in unit dose blisters comprised of laminate blister film and foil lidding.
Blisterarket består af klar polychlortrifluorethylen/ polyvinyl chlorid (PCTFE/ PVC) film, forseglet med en varmeforsegling af vinyl betrukket med aluminiumsfolie.
The blister consists of clear polychlortrifluorethylene/ polyvinyl chloride (PCTFE/ PVC) film, sealed with a vinyl heat seal coated aluminum foil.
Papir og/ eller polyester kan være tilføjet den ydre overflade af folien.
Paper and/ or polyester may be added to the outer surface of the foil.
Pakningstørrelser på 2, 4, 7, 10, 14 og 20 tabletter.
Pack sizes of 2, 4, 7, 10, 14 and 20 tablets.
DATO FOR FØRSTE MAKEDSFØRINGSTILLADELSE/ FORNYELSE AF TILLADELSEN
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
Industriepark 30 2220 Heist- op- den- Berg Belgien
Industriepark 30 2220 Heist-op-den-Berg Belgium
MARKEDSFØRINGSTILLADELSEN VEDRØRENDE UDLEVERING OG BRUG
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
- BETINGELSER ELLER BEGRÆNSNINGER MED HENSYN TIL EN SIKKER OG
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Pharmacovigilance - system
Pharmacovigilance system
Ansøgning om Markedsføringstilladelse, er på plads og fungerer før, og mens produktet er på markedet.
The MAH must ensure that the system of pharmacovigilance, as described in the version dated 21 March 2007 and presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
13 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
LABELLING
KARTON MED 2, 4, 7, 10, 14, 20 TABLETTER MED MODIFICERET UDLØSNING
BOX OF 2, 4, 7, 10, 14, 20 MODIFIED-RELEASE TABLETS
Aerinaze 2, 5 mg/ 120 mg tabletter med modificeret udløsning Desloratadin/ pseudoephedrin (som sulfat)
Aerinaze 2.5 mg/ 120 mg modified-release tablets desloratadine/ pseudoephedrine (as sulphate)
Udløbsdato
15 EXP
14 Opbevares i den ydre karton.
Keep the blisters in the outer carton.
SP Europe Rue de Stalle 73 B- 1180 Bruxelles, Belgien
SP Europe Rue de Stalle 73 B-1180 Bruxelles, Belgium
EU/ 1/ 07/ 399/ 001 2 tabletter med modificeret udløsning EU/ 1/ 07/ 399/ 002 4 tabletter med modificeret udløsning EU/ 1/ 07/ 399/ 003 7 tabletter med modificeret udløsning EU/ 1/ 07/ 399/ 004 10 tabletter med modificeret udløsning EU/ 1/ 07/ 399/ 005 14 tabletter med modificeret udløsning EU/ 1/ 07/ 399/ 006 20 tabletter med modificeret udløsning
EU/ 1/ 07/ 399/ 001 EU/ 1/ 07/ 399/ 002 EU/ 1/ 07/ 399/ 003 EU/ 1/ 07/ 399/ 004 EU/ 1/ 07/ 399/ 005 EU/ 1/ 07/ 399/ 006
INSTRUKTIONER VEDRØRENDE ANVENDELSEN
INFORMATION IN BRAILLE
INFORMATION I BRAILLE- SKRIFT
16 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
17 INDLÆGSSEDDEL:
PACKAGE LEAFLET
Aerinaze 2, 5 mg/ 120 mg tabletter med modificeret udløsning Desloratadin/ pseudoephedrin (som sulfat)
Aerinaze 2.5 mg/ 120 mg modified-release tablet desloratadine/ pseudoephedrine (as sulphate)
- Lægen har ordineret Aerinaze til dig personligt.
- This medicine has been prescribed for you.
Lad derfor være med at give Aerinaze til andre.
It may harm them, even
Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har.
if their symptoms are the same as yours.
- Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
er nævnt her.
please tell your doctor or pharmacist.
Aerinazes virkning og hvad du skal bruge det til 2.
What Aerinaze is and what it is used for 2.
Det skal du vide, før du begynder at tage Aerinaze 3.
Before you take Aerinaze 3.
Sådan skal du tage Aerinaze 4.
How to take Aerinaze 4.
Sådan opbevarer du Aerinaze 6.
How to store Aerinaze 6.
AERINAZES VIRKNING OG HVAD DU SKAL BRUGE DET TIL
WHAT AERINAZE IS AND WHAT IT IS USED FOR
Aerinaze- tabletter indeholder en kombination af to lægemidler, et antihistamin og et dekongestant.
Aerinaze tablets contain a combination of two medicines, an antihistamine and a decongestant.
Dekongestanter letter tilstopning i næsen.
Decongestants help to clear nasal congestion.
Aerinaze- tabletter lindrer symptomer, der er forbundet med sæsonbetinget allergisk rhinitis (høfeber), såsom nysen, løbende eller kløende næse og øjne i forbindelse med tilstoppet næse.
Aerinaze tablets relieve symptoms associated with seasonal allergic rhinitis (hay fever), such as, sneezing, runny or itchy nose, and eyes, when accompanied by nasal congestion.
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE AERINAZE
BEFORE YOU TAKE AERINAZE
Tag ikke Aerinaze
Do not take Aerinaze
- hvis du er overfølsom (allergisk) over for desloratadin, loratadin, pseudoephedrin eller et af de
- if you are allergic (hypersensitive) to desloratadine, loratadine, pseudoephedrine or to any of the
øvrige indholdsstoffer.
other ingredients of Aerinaze.
- hvis du også får hjerte - eller blodtryksmedicin.
- if you are also receiving heart or blood pressure medicine.
- hvis du har glaukom (grå stær), vandladningsbesvær, forsnævret urinrør, højt blodtryk, hjerte -
- if you have glaucoma, difficulty in urinating, urinary tract blockage, high blood pressure, heart or
karsygdomme, tidligere apopleksi eller en overaktiv skjoldbruskkirtel.
blood vessel disease, a history of stroke, or an overactive thyroid.
- Fortæl det til din læge, hvis du får behandling med monoaminoxidase- hæmmere (MAO -
- Tell your doctor if you are receiving monoamine oxidase (MAO) inhibitor (a class of antidepressant
hæmmere) (en type antidepressive midler) eller er stoppet med at tage denne type medicin inden for de sidste 14 dage.
agents) therapy or have stopped taking these types of medicines within the last 14 days.
Vær ekstra forsigtig med at tage Aerinaze Særlige tilstande kan gøre dig usædvanligt følsom over for dekongestanten pseudoephedrin, som findes i dette lægemiddel.
Take special care with Aerinaze Certain conditions may make you unusually sensitive to the decongestant pseudoephedrine contained in this medicine.
Fortæl det til din læge eller apoteket, før du tager Aerinaze:
Before taking Aerinaze, tell your doctor or pharmacist:
- Hvis du er 60 år eller ældre.
- if you are 60 years of age or older.
Ældre voksne kan være mere følsomme over for virkningen af dette
Older adults may be more sensitive to the effects of this
lægemiddel.
medicine.
- Hvis du har øjenproblemer (som øget tryk i øjet eller glaukom), diabetes mellitus (sukkersyge),
- if you have eye problems (such as increased pressure in the eye or glaucoma), diabetes mellitus
stenotisk mavesår (mavesår som fører til indsnævring af maven, tyndtarmen eller spiserøret), pyloral eller duodenal blokade (blokade af tarmene), blokade af blæremunden, tidligere bronkospasme (vejrtrækningsbesvær p. g. a. stramning af lungemusklerne), forstørret blærehalskirtel eller problemer med lever, nyrer eller blære.
(sugar diabetes), stenosing peptic ulcer (ulcer leading to the narrowing of the stomach, small intestine or esophagus), pyloral or duodenal blockage (intestine blockage), vesical cervix blockage
- Hvis du skal have gennemført en planlagt operation, da du måske skal holde pause med
19 (bladder neck blockage), previous history of bronchospasm (difficulty breathing due to tightening of the lung muscles), prostate enlargement or problems with your liver, kidney, or bladder.
Aerinaze et par dage.
- if you are scheduled to have surgery, because you may have to stop taking Aerinaze for a few days.
18
- if you are taking digitalis, a medicine used to treat certain heart disorders, because the dosage may
- Hvis du tager digoxin, et middel mod særlige hjertelidelser, da dosis muligvis skal justeres.
have to be adjusted.
- Hvis du tager α- methyldopa, mecamylamin, reserpin, varatrum alkaloider eller guanethidin for
- if you are taking α -methyldopa, mecamylamine, reserpine, veratrum alkaloids and guanethidine for
blodtrykket, da dosis muligvis skal justeres.
blood pressure, because the dose may need to be adjusted.
- Hvis du tager dekongestanter (gennem munden eller næsen), appetitnedsættende midler
- if you are taking decongestants (oral or nasal), appetite suppressants (diet pills), or amphetamines,
(diætpiller) eller amfetaminer, fordi disse midler sammen med Aerinaze kan øge blodtrykket.
because together with Aerinaze, these medicines may raise your blood pressure.
- Hvis du tager sekalealkaloider (som dihydroergotamin, ergotamin eller methylergometrin) mod
- if you are taking ergot alkaloids (such as dihydroergotamine, ergotamine, or methylergometrine) for
migræne.
migraines.
Sammen med Aerinaze kan disse midler øge blodtrykket.
Together with Aerinaze, these medicines may raise your blood pressure.
- Hvis du tager linezolid (et antibiotikum), bromocriptin (mod infertilitet eller Parkinsons
- if you are taking linezolide (an antibiotic), bromocriptine (for infertility or Parkinson’ s disease),
sygdom), cabergolin, lisurid og pergolid (mod Parkinsons sygdom).
cabergoline, lisuride and pergolide (for Parkinson’ s disease).
- Hvis du tager antacida, da de kan øge virkningen af Aerinaze.
- if you are taking antacids, because they may increase the effectiveness of Aerinaze.
- Hvis du tager kaolin (mod diarré) da det kan nedsætte virkningen af Aerinaze.
- if you are taking kaolin (for diarrhoea), because it may lower the effectiveness of Aerinaze.
Fortæl det til lægen, hvis du oplever eller har fået diagnosticeret nogle af følgende: • højt blodtryk • hurtig eller bankende hjerterytme • unormal hjerterytme • føler dig syg, får hovedpine eller forværret hovedpine mens du bruger Aerinaze.
Tell your doctor if you experience or are diagnosed with any of the following: • high blood pressure • a fast or pounding heart beat • abnormal heart rhythm • feeling sick and headache or increase headache while using Aerinaze.
Din læge vil måske anbefale dig at stoppe behandlingen.
Your doctor may advise you to stop your treatment.
Et af stofferne i Aerinaze, pseudoephedrinsulfat kan misbruges, og store doser pseudoephedrinsulfat kan være giftigt.
One of the medicines in Aerinaze, pseudoephedrine sulphate, has the potential to be abused and large doses of pseudoephedrine sulphate can be toxic.
Laboratorieprøver Stop brugen af Aerinaze mindst 48 timer før du får foretaget hudprøver.
Laboratory Tests Stop taking Aerinaze at least 48 hours before you have any skin tests.
Brug af Aerinaze sammen med mad og drikke Aerinaze- tabletter kan tages med eller uden mad.
Taking Aerinaze with food and drink Aerinaze tablets may be taken with or without food.
Graviditet og amning Spørg din læge eller apotek til råds, før du tager nogen form for medicin under graviditet eller amning.
Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine during pregnancy or breast-feeding.
Du bør ikke tage Aerinaze, hvis du er gravid.
Taking Aerinaze is not recommended if you are pregnant.
Nedsat mælkeproduktion hos ammende mødre er blevet set med pseudoephedrin, som er en bestanddel af Aerinaze.
Decreased milk production in nursing mothers has been reported with pseudoephedrine, a component of Aerinaze.
Trafik - og arbejdssikkerhed Ved den anbefalede dosis forventes det ikke, at Aerinaze gør dig døsig eller mindre agtpågiven.
Driving and using machines At the recommended dose, Aerinaze is not expected to cause you to be drowsy or less alert.
I meget sjældne tilfælde oplever nogle personer imidlertid døsighed, som kan påvirke deres evne til at køre bil eller arbejde med maskiner.
However, very rarely some people experience drowsiness, which may affect their ability to drive or use machines.
SÅDAN SKAL DU TAGE AERINAZE
HOW TO TAKE AERINAZE
Tag/ brug altid Aerinaze nøjagtigt efter lægens anvisning.
20 Always take Aerinaze tablets exactly as your doctor has told you.
Er du i tvivl så spørg lægen eller apoteket.
You should check with your doctor or pharmacist if you are not sure.
Voksne og unge over 12 år:
Adults and adolescents 12 years of age and over:
Tag en Aerinaze- tablet to gange daglig med et glas vand med eller uden mad.
Take one Aerinaze tablet twice daily with a glass of water, with or without food.
Slug tabletten hel; knus, del eller tyg ikke tabletten, før den synkes.
Swallow the tablet whole; do not crush, break or chew the tablet before swallowing.
Aerinaze bør ikke anvendes til børn under 12 år.
Aerinaze should not be used in children less than 12 years of age.
Tag ikke flere Aerinaze- tabletter end anbefalet på etiketten.
Do not take more Aerinaze tablets than recommended on the label.
Tag ikke tabletter oftere end anbefalet.
Do not take Aerinaze tablets more often than recommended.
19 Tag ikke dette lægemiddel i mere end 10 dage i træk, med mindre lægen siger det.
Do not take this medicine for more than 10 days continuously unless your doctor tells you to do so.
Hvis du har taget for mange Aerinaze Kontakt lægen eller apoteket, hvis du har taget for mange Aerinaze- tabletter.
If you take more Aerinaze than you should If you take more Aerinaze than you were told to, tell your doctor or pharmacist immediately.
Hvis du har glemt at tage Aerinaze Hvis du glemmer at tage dosis til tiden, så tag den så hurtigt som muligt og fortsæt med din sædvanlige dosering.
If you forget to take Aerinaze If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule.
Spørg lægen eller apoteket hvis der er noget, du er i tvivl om eller føler dig usikker på.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Aerinaze kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Aerinaze can cause side effects, although not everybody gets them.